Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions: ABP 938, Aflibercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 50 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Fullerton, California • La Jolla, California + 36 more

Conditions: Macular Degeneration, Age-Related, Geographic Atrophy
Interventions: Galegenimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 48
States / cities: Bakersfield, California • Encino, California • Fullerton, California + 43 more

Conditions: Macular Edema, Macular Degeneration
Interventions: Ranibizumab; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Age-Related Macular Degeneration
Interventions: Squalamine Lactate Ophthalmic Solution, 0.2%, Placebo Ophthalmic Solution, ranibizumab; Drug
Lead sponsor: Ohr Pharmaceutical Inc.; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Beverly Hills, California • Hagerstown, Maryland • New York, New York + 1 more

Conditions: Macular Edema, Uveitis
Interventions: Periocular triamcinolone 40 mg, Intravitreal triamcinolone 4 mg, Dexamethasone intravitreal implant; Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 17 more

Conditions: Retinopathy of Prematurity
Interventions: Handheld Optical Coherence Tomography with OCT Angiography; Device
Lead sponsor: Duke University; Other
Eligibility: Up to 2 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphi, Pennsylvania

Conditions: Retinal Vein Occlusion, Macular Edema
Interventions: dexamethasone intravitreal implant 0.7 mg; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetic Macular Edema
Interventions: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation; Drug · Procedure
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 51
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more

Conditions: Retinitis Pigmentosa (RP), Usher Syndrome
Interventions: Placebo, NPI-001; Drug
Lead sponsor: Nacuity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions: FYB203 2 mg (0.05 mL of 40 mg/mL); Drug
Lead sponsor: Formycon AG; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 4
States / cities: Campbell, California • Long Beach, California • Redlands, California + 1 more

Conditions: Diabetic Retinopathy, Diabetes Mellitus
Interventions: Aim 3: Contract; Behavioral
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 107
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more

Conditions: Macular Degeneration
Interventions: NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks; Drug
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more

Conditions: Age-Related Macular Degeneration
Interventions: ranibizumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more

Conditions: Retinal Vein Occlusion
Interventions: Nicotinic acid, Prednisolone acetate; Drug
Lead sponsor: Palo Alto Medical Foundation; Other
Eligibility: Not listed
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hippel-Lindau Disease
Interventions: EYE001; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Diseases, Optic Nerve Diseases
Interventions: Duke Biomedical Engineering's Long-working distance OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 6 Months and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Age-related Macular Degeneration
Interventions: Squalamine lactate ophthalmic solution, 0.2%, Placebo Ophthalmic solution, ranibizumab; Drug
Lead sponsor: Ohr Pharmaceutical Inc.; Industry
Eligibility: 50 Years to 110 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 118
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 106 more

Conditions: Pediatric Retinoblastoma, Retinoblastoma
Interventions: Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V), California Verbal Learning Test, Children's Version, Beery Developmental Test of Visual Motor Integration, 6th edition, Grooved Pegboard Test, Behavior Assessment System for Children/Parent Report; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth, Bronchopulmonary Dysplasia, Retinopathy of Prematurity
Interventions: Surfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%, Supplemental oxygen with target saturation of 91 to 95%; Drug · Device
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 24 Weeks to 27 Weeks
Enrollment: 1,316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 18 more

Conditions: Chondrosarcoma, Osteosarcoma, Soft Tissue Sarcoma
Interventions: Abemaciclib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 4
States / cities: Jacksonville, Florida • Iowa City, Iowa • St Louis, Missouri + 1 more

Conditions: Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
Interventions: Ofatumumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Diabetes Mellitus
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Geographic Atrophy
Interventions: Lampalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years to 89 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 41
States / cities: Tucson, Arizona • Beverly Hills, California • Campbell, California + 37 more

Search by objective public record fields.

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

Imaging Retinal Vasculature in Infant Eyes

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Ocular Safety and Usability Study for FYB203 PFS

Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Long-Working Distance OCT for Children

Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients

Surfactant Positive Airway Pressure and Pulse Oximetry Trial

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Progression of Diabetic Retinopathy Post Bariatric Surgery (BS)

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy